Incretin Atlas › Trials › SOLSTICE (NCT06579105)
SOLSTICE (NCT06579105)
AZD5004 (ECC5004) · t2d
Design
- Molecule(s)
- AZD5004 (ECC5004)
- Population
- t2d
- Phase
- 2
- Participants
- 406
- Duration
- 26 weeks
- Registry
- NCT06579105
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −2.9 % vs −1.7 % Δ −1.2 pp | — | −0.9 vs −0.1 | — | — | — | — | — | — | press release |
| 15 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −3.4 % vs −1.7 % Δ −1.7 pp | — | −1.1 vs −0.1 | — | — | — | — | — | — | press release |
| 25 mg QD vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −4.0 % vs −1.7 % Δ −2.3 pp | — | −1.2 vs −0.1 | — | — | — | — | — | — | press release |
| 50 mg QD (escalated every 2 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −5.9 % vs −1.7 % Δ −4.2 pp | — | −1.4 vs −0.1 | — | — | — | — | — | — | press release |
| 75 mg QD (escalated every 2 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −7.7 % vs −1.7 % Δ −6.0 pp | — | −1.9 vs −0.1 | — | — | 37.0 vs 3.0 | 18.0 vs 1.0 | — | — | press release |
| 75 mg QD (escalated every 4 weeks) vs oral semaglutide 14 mg QD (open-label exploratory comparator): weight -5.1 %, HbA1c -1.3 | t2d | 26 | 406 | −7.0 % vs −1.7 % Δ −5.3 pp | — | −1.6 vs −0.1 | — | — | — | — | — | — | press release |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Notes
- 75 mg QD (escalated every 2 weeks): GI events from the release, which reports them for «elecoglipron 75 mg» (matched to this arm by its HbA1c and weight).
Verbatim quotes from the source (14)
- 5 mg QD · hba1c · publication (abstract)
change from baseline in HbA1c ranged between -0·91% (95% CI -1·25 to -0·58; 5 mg elecoglipron)
- 5 mg QD · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 15 mg QD · hba1c · press release
| -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
- 15 mg QD · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 25 mg QD · hba1c · press release
| -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
- 25 mg QD · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 50 mg QD (escalated every 2 weeks) · hba1c · press release
| -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
- 50 mg QD (escalated every 2 weeks) · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 75 mg QD (escalated every 2 weeks) · hba1c · publication (abstract)
-1·88% (-2·23 to -1·53; 75 mg elecoglipron with every 2-week dose-escalation step) compared with -0·15% (-0·42 to 0·12) with placebo
- 75 mg QD (escalated every 2 weeks) · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
- 75 mg QD (escalated every 2 weeks) · nausea · press release, safety paragraph (SOLSTICE)
In SOLSTICE, the most common adverse events with elecoglipron (75mg) compared to placebo were nausea (37%, 3%), constipation (29%, 4%), diarrhoea (21%, 15%) and vomiting (18%, 1%)
- 75 mg QD (escalated every 2 weeks) · vomiting · press release, safety paragraph (SOLSTICE)
In SOLSTICE, the most common adverse events with elecoglipron (75mg) compared to placebo were nausea (37%, 3%), constipation (29%, 4%), diarrhoea (21%, 15%) and vomiting (18%, 1%)
- 75 mg QD (escalated every 4 weeks) · hba1c · press release
| -0.9% | -1.1% | -1.2 | -1.4% | -1.9% | -1.6% | -0.2% | -1.3%
- 75 mg QD (escalated every 4 weeks) · weight_eff · press release
| -2.9% | -3.4% | -4.0% | -5.9% | -7.7% | -7.0% | -1.7% | -5.1%
Primary sources
- AstraZeneca (licensed from Eccogene). AstraZeneca: Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme (VISTA and SOLSTICE Phase IIb results; Cision mirror) [press release]. 2026-06-08. Available from: https://news.cision.com/se/astrazeneca/r/elecoglipron--an-oral-small-molecule-glp-1-ra--moves-to-phase-iii-programme-and-unlocks-next-chapter,c4359385
- Aroda VR, Davies MJ, Maaske J, Millegård M, Juan VL, Aberle J, et al. Elecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial. Lancet. 2026;407(10547):2515-2527. PMID: 42259343.
How to cite this page
Medical Adviser's Group. Incretin Atlas: SOLSTICE (NCT06579105). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/solstice/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.